Specialty Pharmacy

The recent discovery could aid further research on the cause of Huntington’s disease and other inherited conditions.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Generative artificial intelligence is a type of self-learning software that can increase the time pharmacists can allocate to patients, improve medication adherence, and allow patients to access health data on a whim.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Expert weighs in on the growth of specialty drug spending, particularly with drugs in immunology, neurology, and weight loss.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Pharmacists can improve patient access to both healthful foods and necessary medicines as a continuum of care in underserved communities.

Educator and pharmacy advocate encourages pharmacists to work together to improve the scope of the profession and patient access to services.

Although additional studies are needed, findings indicate that mtDNAfb may be a useful biomarker for future risk of non-Hodgkin lymphoma.

Improved prescription information could help consumers make better health care decisions and result in cost savings.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

Specialty pharmacists play an important role in dispensing PCSK9 inhibitors and serve as a valuable source of assistance and education for patients.

In terms of science and technology, the health care community has everything needed to clinically implement pharmacogenomics testing.

Risks of genitourinary and gastrointestinal toxicity were reduced significantly, but longer follow-up is necessary to examine potential future issues.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Managing cost savings can soften the blow of direct and indirect remuneration fee reform that will impact pharmacists during the first half of 2024.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Specialty pharmacists can have more contact with patients than providers.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Drug shortages have led to increased use of compounding pharmacy.

Quality standards and national regulation help to establish its role as medicine.

Evidence remains limited for specific therapies to treat the disease, but new clinical trials are ongoing.

Those infected with HIV could have experienced more hardships during the peak of the pandemic and could suffer more challenges with the lack of resources post-pandemic.

Express Scripts recently announced the addition of 3 Humira biosimilars to its main formulary.

Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.

Albumin is a cost-effective predictor of intravenous immunoglobulin-resistance in young patients with Kawasaki disease.